 Lisa Bero
Concepts (694)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Conflict of Interest | 80 | 2023 | 120 | 23.340 |
Why?
| | Drug Industry | 59 | 2023 | 104 | 14.960 |
Why?
| | Research Support as Topic | 39 | 2021 | 114 | 9.720 |
Why?
| | Tobacco Industry | 34 | 2018 | 45 | 8.390 |
Why?
| | Industry | 27 | 2024 | 69 | 6.680 |
Why?
| | Publication Bias | 24 | 2020 | 38 | 6.480 |
Why?
| | Publishing | 33 | 2021 | 131 | 6.090 |
Why?
| | Disclosure | 29 | 2022 | 102 | 6.070 |
Why?
| | Review Literature as Topic | 24 | 2022 | 68 | 5.880 |
Why?
| | Research Design | 32 | 2023 | 969 | 5.880 |
Why?
| | Health Policy | 24 | 2022 | 333 | 5.400 |
Why?
| | Public Health | 28 | 2023 | 450 | 5.040 |
Why?
| | World Health Organization | 23 | 2022 | 107 | 4.920 |
Why?
| | Evidence-Based Medicine | 26 | 2023 | 693 | 4.890 |
Why?
| | Biomedical Research | 24 | 2021 | 612 | 4.610 |
Why?
| | Policy Making | 20 | 2022 | 86 | 4.590 |
Why?
| | Practice Guidelines as Topic | 22 | 2021 | 1440 | 4.130 |
Why?
| | Meta-Analysis as Topic | 17 | 2022 | 164 | 3.870 |
Why?
| | Randomized Controlled Trials as Topic | 24 | 2024 | 1244 | 3.560 |
Why?
| | Bias | 19 | 2024 | 198 | 3.510 |
Why?
| | Mobile Applications | 8 | 2020 | 147 | 3.190 |
Why?
| | Pharmaceutical Preparations | 9 | 2022 | 167 | 3.060 |
Why?
| | Australia | 24 | 2023 | 212 | 2.880 |
Why?
| | Editorial Policies | 10 | 2021 | 46 | 2.860 |
Why?
| | Nutritional Sciences | 6 | 2019 | 36 | 2.840 |
Why?
| | Smoking | 25 | 2016 | 1487 | 2.680 |
Why?
| | Periodicals as Topic | 18 | 2020 | 191 | 2.610 |
Why?
| | Smoking Prevention | 12 | 2012 | 150 | 2.570 |
Why?
| | Environmental Exposure | 6 | 2021 | 405 | 2.530 |
Why?
| | Scientific Misconduct | 4 | 2021 | 10 | 2.520 |
Why?
| | Health Personnel | 10 | 2021 | 588 | 2.480 |
Why?
| | Humans | 254 | 2024 | 118969 | 2.430 |
Why?
| | Food Industry | 6 | 2020 | 14 | 2.400 |
Why?
| | Nutrition Policy | 5 | 2020 | 58 | 2.310 |
Why?
| | Observational Studies as Topic | 6 | 2024 | 89 | 2.280 |
Why?
| | Clinical Trials as Topic | 18 | 2021 | 968 | 2.260 |
Why?
| | Research Report | 5 | 2019 | 75 | 2.190 |
Why?
| | Equipment and Supplies | 8 | 2020 | 39 | 2.180 |
Why?
| | Environmental Health | 7 | 2019 | 37 | 2.130 |
Why?
| | Information Dissemination | 10 | 2021 | 210 | 2.050 |
Why?
| | United States Food and Drug Administration | 14 | 2015 | 175 | 2.000 |
Why?
| | Marketing | 9 | 2021 | 25 | 1.970 |
Why?
| | Guideline Adherence | 8 | 2019 | 523 | 1.960 |
Why?
| | Tobacco Smoke Pollution | 16 | 2006 | 233 | 1.840 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 5 | 2018 | 387 | 1.820 |
Why?
| | Ethics, Research | 5 | 2020 | 31 | 1.780 |
Why?
| | Environmental Pollutants | 6 | 2018 | 120 | 1.730 |
Why?
| | Government Regulation | 12 | 2019 | 47 | 1.680 |
Why?
| | Drugs, Essential | 5 | 2018 | 6 | 1.660 |
Why?
| | Propaganda | 3 | 2019 | 3 | 1.650 |
Why?
| | Public Policy | 7 | 2016 | 62 | 1.640 |
Why?
| | Research | 18 | 2020 | 411 | 1.580 |
Why?
| | Politics | 8 | 2020 | 80 | 1.510 |
Why?
| | Peer Review, Research | 9 | 2015 | 35 | 1.480 |
Why?
| | Data Collection | 9 | 2019 | 658 | 1.440 |
Why?
| | Evidence-Based Practice | 4 | 2020 | 193 | 1.370 |
Why?
| | United States | 64 | 2021 | 12554 | 1.370 |
Why?
| | Authorship | 10 | 2020 | 36 | 1.370 |
Why?
| | Physicians | 12 | 2023 | 793 | 1.340 |
Why?
| | Nutritional Status | 5 | 2020 | 300 | 1.330 |
Why?
| | Guidelines as Topic | 7 | 2020 | 262 | 1.320 |
Why?
| | Coronavirus Infections | 4 | 2021 | 339 | 1.310 |
Why?
| | Qualitative Research | 12 | 2023 | 953 | 1.300 |
Why?
| | Delivery of Health Care | 5 | 2024 | 867 | 1.280 |
Why?
| | Cross-Sectional Studies | 27 | 2021 | 4552 | 1.280 |
Why?
| | Bibliometrics | 5 | 2018 | 51 | 1.260 |
Why?
| | Commerce | 8 | 2020 | 56 | 1.240 |
Why?
| | Pharmacy and Therapeutics Committee | 2 | 2020 | 3 | 1.240 |
Why?
| | Vitamin D | 2 | 2021 | 354 | 1.190 |
Why?
| | Community Pharmacy Services | 2 | 2022 | 46 | 1.180 |
Why?
| | Interprofessional Relations | 5 | 2021 | 261 | 1.150 |
Why?
| | Risk Management | 2 | 2022 | 90 | 1.140 |
Why?
| | Research Personnel | 4 | 2017 | 158 | 1.140 |
Why?
| | Drug Approval | 5 | 2015 | 77 | 1.120 |
Why?
| | Occupational Health | 5 | 2019 | 172 | 1.110 |
Why?
| | Health Promotion | 8 | 2019 | 691 | 1.110 |
Why?
| | Cardiovascular Diseases | 7 | 2021 | 1798 | 1.100 |
Why?
| | Education, Medical, Continuing | 4 | 2019 | 125 | 1.100 |
Why?
| | Bone and Bones | 2 | 2021 | 289 | 1.070 |
Why?
| | Deprescriptions | 5 | 2023 | 27 | 1.050 |
Why?
| | Lobbying | 6 | 2006 | 8 | 1.040 |
Why?
| | Interrupted Time Series Analysis | 7 | 2022 | 45 | 1.030 |
Why?
| | Practice Patterns, Physicians' | 12 | 2021 | 1199 | 1.010 |
Why?
| | Diet | 5 | 2020 | 1153 | 1.000 |
Why?
| | Policy | 3 | 2020 | 133 | 0.990 |
Why?
| | Toxicity Tests | 3 | 2016 | 26 | 0.980 |
Why?
| | Medical Overuse | 4 | 2019 | 31 | 0.970 |
Why?
| | Financial Support | 5 | 2019 | 21 | 0.970 |
Why?
| | Risk Assessment | 10 | 2022 | 3057 | 0.970 |
Why?
| | Spinal Cord Stimulation | 1 | 2024 | 7 | 0.960 |
Why?
| | Workplace | 4 | 2009 | 222 | 0.950 |
Why?
| | Consumer Advocacy | 2 | 2020 | 12 | 0.930 |
Why?
| | Telemedicine | 4 | 2019 | 664 | 0.920 |
Why?
| | Formularies as Topic | 3 | 2018 | 6 | 0.920 |
Why?
| | Pandemics | 7 | 2023 | 1354 | 0.910 |
Why?
| | Codeine | 1 | 2022 | 6 | 0.900 |
Why?
| | Health Education | 2 | 2018 | 318 | 0.870 |
Why?
| | Dietary Supplements | 2 | 2021 | 467 | 0.870 |
Why?
| | Health Priorities | 2 | 2012 | 34 | 0.860 |
Why?
| | Epidemiologic Methods | 2 | 2022 | 72 | 0.860 |
Why?
| | Drug Evaluation | 5 | 2012 | 81 | 0.850 |
Why?
| | Confidentiality | 2 | 2021 | 67 | 0.830 |
Why?
| | Decision Making | 9 | 2014 | 809 | 0.820 |
Why?
| | Retraction of Publication as Topic | 1 | 2021 | 1 | 0.810 |
Why?
| | Recommended Dietary Allowances | 1 | 2021 | 16 | 0.810 |
Why?
| | Group Practice | 1 | 2021 | 7 | 0.790 |
Why?
| | Interviews as Topic | 7 | 2019 | 599 | 0.790 |
Why?
| | Attitude | 4 | 2013 | 231 | 0.790 |
Why?
| | Advisory Committees | 6 | 2020 | 212 | 0.780 |
Why?
| | Tobacco Products | 3 | 2018 | 69 | 0.770 |
Why?
| | Bone Remodeling | 1 | 2021 | 64 | 0.770 |
Why?
| | Technology Transfer | 2 | 2019 | 13 | 0.770 |
Why?
| | Contact Tracing | 1 | 2020 | 16 | 0.770 |
Why?
| | Atherosclerosis | 2 | 2015 | 345 | 0.760 |
Why?
| | Gift Giving | 2 | 2019 | 9 | 0.750 |
Why?
| | Checklist | 1 | 2021 | 81 | 0.750 |
Why?
| | Calcium | 2 | 2021 | 1169 | 0.740 |
Why?
| | Betacoronavirus | 2 | 2020 | 254 | 0.740 |
Why?
| | Science | 3 | 2007 | 49 | 0.740 |
Why?
| | Societies, Scientific | 1 | 2020 | 49 | 0.730 |
Why?
| | Societies | 1 | 2020 | 42 | 0.730 |
Why?
| | Organizational Policy | 7 | 2011 | 70 | 0.730 |
Why?
| | Beverages | 2 | 2019 | 70 | 0.730 |
Why?
| | Marketing of Health Services | 3 | 2018 | 15 | 0.710 |
Why?
| | Dental Research | 1 | 2019 | 7 | 0.710 |
Why?
| | Attitude to Health | 6 | 2015 | 410 | 0.710 |
Why?
| | Whole Grains | 1 | 2019 | 3 | 0.710 |
Why?
| | Calcium, Dietary | 1 | 2019 | 55 | 0.710 |
Why?
| | Off-Label Use | 3 | 2015 | 48 | 0.700 |
Why?
| | Patient Advocacy | 2 | 2019 | 66 | 0.700 |
Why?
| | Databases, Factual | 5 | 2020 | 1231 | 0.700 |
Why?
| | Selection Bias | 2 | 2017 | 35 | 0.690 |
Why?
| | Pharmacists | 7 | 2022 | 238 | 0.690 |
Why?
| | Hazardous Substances | 2 | 2018 | 12 | 0.680 |
Why?
| | Tobacco Use Disorder | 4 | 2010 | 233 | 0.670 |
Why?
| | Public Opinion | 6 | 2015 | 59 | 0.670 |
Why?
| | Analgesics, Opioid | 7 | 2023 | 793 | 0.670 |
Why?
| | Journalism | 2 | 2012 | 5 | 0.660 |
Why?
| | International Cooperation | 7 | 2011 | 177 | 0.660 |
Why?
| | Internet | 4 | 2019 | 633 | 0.660 |
Why?
| | Gynecology | 1 | 2021 | 184 | 0.660 |
Why?
| | Developing Countries | 4 | 2018 | 255 | 0.660 |
Why?
| | Professional Role | 4 | 2022 | 153 | 0.650 |
Why?
| | Vitamins | 1 | 2019 | 158 | 0.650 |
Why?
| | Nicotine | 8 | 2006 | 276 | 0.650 |
Why?
| | Food Analysis | 1 | 2018 | 18 | 0.650 |
Why?
| | Cooperative Behavior | 3 | 2013 | 408 | 0.640 |
Why?
| | Quality Control | 8 | 2013 | 159 | 0.640 |
Why?
| | Fluorocarbons | 2 | 2023 | 105 | 0.640 |
Why?
| | Health Behavior | 4 | 2021 | 720 | 0.640 |
Why?
| | Writing | 2 | 2019 | 88 | 0.640 |
Why?
| | Pneumonia, Viral | 2 | 2020 | 348 | 0.640 |
Why?
| | Pharmaceutical Services | 3 | 2013 | 79 | 0.630 |
Why?
| | Access to Information | 3 | 2014 | 53 | 0.630 |
Why?
| | Capital Financing | 1 | 2017 | 6 | 0.630 |
Why?
| | Health Services | 3 | 2013 | 110 | 0.630 |
Why?
| | Databases, Bibliographic | 3 | 2014 | 29 | 0.630 |
Why?
| | Disease Outbreaks | 1 | 2020 | 322 | 0.610 |
Why?
| | Nurses | 2 | 2016 | 142 | 0.610 |
Why?
| | Population Health | 1 | 2018 | 46 | 0.610 |
Why?
| | Cannabis | 1 | 2023 | 382 | 0.590 |
Why?
| | Interinstitutional Relations | 5 | 2013 | 55 | 0.590 |
Why?
| | Peer Review | 5 | 2015 | 40 | 0.590 |
Why?
| | Opioid-Related Disorders | 2 | 2023 | 417 | 0.590 |
Why?
| | Vaccines | 1 | 2022 | 380 | 0.590 |
Why?
| | Government Agencies | 2 | 2015 | 14 | 0.580 |
Why?
| | Drug Evaluation, Preclinical | 2 | 2015 | 180 | 0.580 |
Why?
| | Tobacco Use Cessation | 1 | 2016 | 21 | 0.570 |
Why?
| | Primary Prevention | 1 | 2018 | 185 | 0.570 |
Why?
| | Sweetening Agents | 1 | 2016 | 52 | 0.560 |
Why?
| | Drug Prescriptions | 4 | 2022 | 248 | 0.560 |
Why?
| | Atrazine | 1 | 2015 | 8 | 0.550 |
Why?
| | California | 9 | 2013 | 382 | 0.550 |
Why?
| | Libraries, Digital | 2 | 2012 | 4 | 0.550 |
Why?
| | Drug Overdose | 1 | 2020 | 294 | 0.540 |
Why?
| | Medicaid | 4 | 2013 | 411 | 0.540 |
Why?
| | Pharmacies | 1 | 2015 | 31 | 0.530 |
Why?
| | Databases, Pharmaceutical | 1 | 2015 | 5 | 0.530 |
Why?
| | Patient Care Planning | 1 | 2016 | 143 | 0.530 |
Why?
| | Fetal Development | 2 | 2016 | 250 | 0.520 |
Why?
| | Epidemiologic Studies | 2 | 2022 | 58 | 0.520 |
Why?
| | Fees, Pharmaceutical | 2 | 2014 | 13 | 0.520 |
Why?
| | Models, Organizational | 2 | 2008 | 146 | 0.520 |
Why?
| | Cohort Studies | 7 | 2022 | 5115 | 0.520 |
Why?
| | Information Services | 4 | 2002 | 46 | 0.520 |
Why?
| | Anticoagulants | 1 | 2019 | 559 | 0.510 |
Why?
| | Academic Medical Centers | 4 | 2018 | 422 | 0.510 |
Why?
| | Air Pollution, Indoor | 2 | 2009 | 117 | 0.510 |
Why?
| | Medication Adherence | 1 | 2019 | 556 | 0.510 |
Why?
| | Canada | 7 | 2022 | 340 | 0.500 |
Why?
| | Knowledge | 2 | 2012 | 59 | 0.500 |
Why?
| | Plants, Toxic | 7 | 2001 | 28 | 0.500 |
Why?
| | Caprylates | 1 | 2014 | 26 | 0.500 |
Why?
| | Obesity | 3 | 2017 | 2746 | 0.490 |
Why?
| | Teaching Materials | 2 | 2007 | 26 | 0.490 |
Why?
| | Quality of Health Care | 4 | 2012 | 586 | 0.490 |
Why?
| | Expert Testimony | 3 | 2020 | 56 | 0.490 |
Why?
| | Occupational Exposure | 3 | 2022 | 277 | 0.490 |
Why?
| | Treatment Outcome | 15 | 2018 | 9342 | 0.480 |
Why?
| | Universities | 4 | 2007 | 347 | 0.480 |
Why?
| | Depressive Disorder, Major | 1 | 2017 | 303 | 0.480 |
Why?
| | Social Support | 1 | 2017 | 542 | 0.470 |
Why?
| | Counseling | 1 | 2016 | 353 | 0.470 |
Why?
| | Community Participation | 2 | 2010 | 120 | 0.460 |
Why?
| | Mass Media | 5 | 2001 | 38 | 0.460 |
Why?
| | Cyclohexanecarboxylic Acids | 3 | 2009 | 23 | 0.460 |
Why?
| | Ambulatory Care | 3 | 2010 | 482 | 0.460 |
Why?
| | Amines | 3 | 2009 | 41 | 0.450 |
Why?
| | Substance-Related Disorders | 7 | 2016 | 971 | 0.450 |
Why?
| | Financial Management | 3 | 2012 | 16 | 0.450 |
Why?
| | Cholesterol, LDL | 1 | 2014 | 316 | 0.440 |
Why?
| | Angiogenesis Inhibitors | 1 | 2014 | 219 | 0.440 |
Why?
| | Macular Degeneration | 1 | 2014 | 151 | 0.440 |
Why?
| | Carcinogens | 2 | 2020 | 108 | 0.440 |
Why?
| | Overweight | 1 | 2016 | 502 | 0.440 |
Why?
| | Thinking | 1 | 2013 | 54 | 0.430 |
Why?
| | Attitude of Health Personnel | 7 | 2023 | 992 | 0.430 |
Why?
| | gamma-Aminobutyric Acid | 3 | 2009 | 155 | 0.430 |
Why?
| | Health Services Accessibility | 4 | 2015 | 781 | 0.420 |
Why?
| | Device Approval | 4 | 2015 | 21 | 0.420 |
Why?
| | Global Health | 3 | 2020 | 310 | 0.420 |
Why?
| | Medication Therapy Management | 1 | 2013 | 72 | 0.420 |
Why?
| | Body Weight | 1 | 2016 | 934 | 0.420 |
Why?
| | Federal Government | 3 | 2009 | 26 | 0.410 |
Why?
| | Human Experimentation | 2 | 2009 | 12 | 0.410 |
Why?
| | Birth Weight | 1 | 2014 | 465 | 0.400 |
Why?
| | Publications | 3 | 2020 | 42 | 0.400 |
Why?
| | Oncologists | 2 | 2021 | 31 | 0.400 |
Why?
| | Organizations, Nonprofit | 1 | 2011 | 18 | 0.390 |
Why?
| | Prejudice | 3 | 2017 | 56 | 0.390 |
Why?
| | Thrombosis | 1 | 2014 | 309 | 0.390 |
Why?
| | Health Knowledge, Attitudes, Practice | 6 | 2021 | 1185 | 0.390 |
Why?
| | Decision Support Techniques | 1 | 2014 | 364 | 0.380 |
Why?
| | Decision Making, Organizational | 2 | 2007 | 25 | 0.380 |
Why?
| | Relief Work | 1 | 2010 | 21 | 0.380 |
Why?
| | Patient Education as Topic | 2 | 2013 | 699 | 0.380 |
Why?
| | Teaching | 1 | 2013 | 236 | 0.370 |
Why?
| | Public Relations | 5 | 2017 | 6 | 0.370 |
Why?
| | Child Welfare | 1 | 2012 | 199 | 0.370 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2014 | 667 | 0.360 |
Why?
| | Drug Labeling | 2 | 2013 | 45 | 0.360 |
Why?
| | Women's Health | 1 | 2012 | 274 | 0.360 |
Why?
| | Congresses as Topic | 4 | 1997 | 204 | 0.360 |
Why?
| | Cluster Analysis | 1 | 2011 | 481 | 0.360 |
Why?
| | Health Care Sector | 2 | 2020 | 26 | 0.360 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 5 | 2014 | 245 | 0.350 |
Why?
| | Prescription Drugs | 4 | 2017 | 113 | 0.350 |
Why?
| | Economic Development | 1 | 2009 | 3 | 0.350 |
Why?
| | Occupational Diseases | 2 | 2022 | 136 | 0.340 |
Why?
| | Ethics, Institutional | 1 | 2009 | 4 | 0.340 |
Why?
| | Social Control Policies | 1 | 2008 | 1 | 0.340 |
Why?
| | Ethics, Professional | 1 | 2009 | 15 | 0.340 |
Why?
| | Poverty | 2 | 2010 | 444 | 0.340 |
Why?
| | Health Care Costs | 4 | 2019 | 394 | 0.340 |
Why?
| | Restaurants | 1 | 2008 | 17 | 0.340 |
Why?
| | Life Style | 2 | 2021 | 430 | 0.340 |
Why?
| | Law Enforcement | 1 | 2008 | 39 | 0.330 |
Why?
| | Neoplasms | 8 | 2023 | 2179 | 0.320 |
Why?
| | Thiazolidinediones | 1 | 2009 | 146 | 0.320 |
Why?
| | Morals | 1 | 2009 | 67 | 0.320 |
Why?
| | Laboratories | 1 | 2009 | 97 | 0.320 |
Why?
| | Uncertainty | 2 | 2021 | 101 | 0.310 |
Why?
| | Trust | 2 | 2019 | 113 | 0.310 |
Why?
| | Ethics Committees, Research | 1 | 2007 | 44 | 0.310 |
Why?
| | Research Subjects | 1 | 2007 | 40 | 0.310 |
Why?
| | Privacy | 3 | 2020 | 31 | 0.300 |
Why?
| | Drug and Narcotic Control | 3 | 2021 | 28 | 0.300 |
Why?
| | Consumer Organizations | 1 | 2007 | 1 | 0.300 |
Why?
| | Smoking Cessation | 5 | 2018 | 360 | 0.300 |
Why?
| | Minority Groups | 1 | 2009 | 237 | 0.300 |
Why?
| | Osteoporosis | 3 | 2021 | 229 | 0.300 |
Why?
| | Deception | 1 | 2007 | 15 | 0.300 |
Why?
| | Nutritional Physiological Phenomena | 2 | 2017 | 54 | 0.300 |
Why?
| | Europe | 4 | 2021 | 356 | 0.290 |
Why?
| | Health Status Disparities | 1 | 2009 | 209 | 0.290 |
Why?
| | Books | 1 | 2006 | 3 | 0.290 |
Why?
| | Aerospace Medicine | 1 | 2006 | 20 | 0.290 |
Why?
| | Aircraft | 1 | 2006 | 28 | 0.280 |
Why?
| | United States Dept. of Health and Human Services | 1 | 2006 | 3 | 0.280 |
Why?
| | Adolescent Behavior | 2 | 2002 | 482 | 0.280 |
Why?
| | Nonprescription Drugs | 1 | 2006 | 67 | 0.270 |
Why?
| | Consumer Product Safety | 3 | 2019 | 31 | 0.270 |
Why?
| | Insurance Claim Reporting | 1 | 2005 | 24 | 0.270 |
Why?
| | MEDLINE | 3 | 2014 | 25 | 0.270 |
Why?
| | Disease | 2 | 2019 | 98 | 0.270 |
Why?
| | Documentation | 4 | 2018 | 175 | 0.260 |
Why?
| | Bone Density | 1 | 2009 | 449 | 0.260 |
Why?
| | Drug Utilization | 3 | 2022 | 169 | 0.260 |
Why?
| | Data Interpretation, Statistical | 3 | 2017 | 336 | 0.260 |
Why?
| | Harm Reduction | 1 | 2004 | 25 | 0.250 |
Why?
| | Animals | 19 | 2020 | 33381 | 0.250 |
Why?
| | International Classification of Diseases | 1 | 2005 | 122 | 0.250 |
Why?
| | Case-Control Studies | 2 | 2024 | 3171 | 0.240 |
Why?
| | Antihypertensive Agents | 1 | 2007 | 437 | 0.240 |
Why?
| | Receptors, Opioid | 3 | 1988 | 18 | 0.240 |
Why?
| | Evaluation Studies as Topic | 3 | 2019 | 182 | 0.240 |
Why?
| | Data Accuracy | 2 | 2021 | 56 | 0.240 |
Why?
| | Cost-Benefit Analysis | 4 | 2015 | 554 | 0.240 |
Why?
| | Consultants | 2 | 2020 | 13 | 0.240 |
Why?
| | Quarantine | 2 | 2020 | 25 | 0.230 |
Why?
| | Data Mining | 2 | 2015 | 113 | 0.230 |
Why?
| | Sample Size | 2 | 2014 | 133 | 0.230 |
Why?
| | Prolactin | 4 | 1987 | 96 | 0.230 |
Why?
| | Journal Impact Factor | 3 | 2020 | 28 | 0.230 |
Why?
| | State Government | 3 | 2009 | 41 | 0.230 |
Why?
| | Drug Therapy | 5 | 2011 | 76 | 0.230 |
Why?
| | Estonia | 2 | 2012 | 2 | 0.220 |
Why?
| | Private Sector | 2 | 2000 | 51 | 0.220 |
Why?
| | Mental Health | 2 | 2019 | 568 | 0.220 |
Why?
| | Alcohol Drinking | 1 | 2008 | 652 | 0.220 |
Why?
| | Schizophrenia | 1 | 2007 | 501 | 0.220 |
Why?
| | Datasets as Topic | 2 | 2020 | 103 | 0.220 |
Why?
| | Health Status | 2 | 2021 | 726 | 0.220 |
Why?
| | Program Development | 2 | 2016 | 357 | 0.220 |
Why?
| | Artificial Intelligence | 1 | 2023 | 140 | 0.220 |
Why?
| | Female | 22 | 2023 | 61564 | 0.210 |
Why?
| | Libraries, Medical | 1 | 2002 | 9 | 0.210 |
Why?
| | Risk | 2 | 2016 | 853 | 0.210 |
Why?
| | Torsades de Pointes | 1 | 2022 | 17 | 0.210 |
Why?
| | Analgesics | 1 | 2023 | 159 | 0.210 |
Why?
| | Newspapers as Topic | 2 | 2001 | 10 | 0.210 |
Why?
| | Truth Disclosure | 7 | 2011 | 38 | 0.210 |
Why?
| | Risk Factors | 7 | 2022 | 8999 | 0.210 |
Why?
| | Chemical Industry | 2 | 2013 | 9 | 0.210 |
Why?
| | Child | 9 | 2020 | 19129 | 0.210 |
Why?
| | History, 21st Century | 2 | 2018 | 170 | 0.210 |
Why?
| | Program Evaluation | 4 | 2020 | 845 | 0.200 |
Why?
| | Double-Blind Method | 2 | 2018 | 1687 | 0.200 |
Why?
| | Healthcare Disparities | 2 | 2021 | 496 | 0.200 |
Why?
| | Long QT Syndrome | 1 | 2022 | 57 | 0.200 |
Why?
| | Medical Oncology | 1 | 2023 | 229 | 0.200 |
Why?
| | Facility Regulation and Control | 1 | 2000 | 2 | 0.200 |
Why?
| | Sodium, Dietary | 1 | 2021 | 43 | 0.190 |
Why?
| | Sierra Leone | 1 | 2020 | 2 | 0.190 |
Why?
| | Botswana | 1 | 2020 | 8 | 0.190 |
Why?
| | Infant Formula | 1 | 2021 | 84 | 0.190 |
Why?
| | Administrative Personnel | 1 | 2020 | 33 | 0.190 |
Why?
| | Health Care Surveys | 2 | 2013 | 546 | 0.190 |
Why?
| | Faculty, Medical | 2 | 2000 | 252 | 0.190 |
Why?
| | United States Agency for Healthcare Research and Quality | 1 | 2020 | 9 | 0.190 |
Why?
| | Patient Isolation | 1 | 2020 | 19 | 0.190 |
Why?
| | Male | 18 | 2023 | 57800 | 0.190 |
Why?
| | Thiadiazines | 1 | 2020 | 2 | 0.190 |
Why?
| | Codes of Ethics | 2 | 2018 | 16 | 0.190 |
Why?
| | Whooping Cough | 1 | 2020 | 49 | 0.190 |
Why?
| | Hemorrhagic Fever, Ebola | 1 | 2020 | 34 | 0.190 |
Why?
| | Organizational Case Studies | 3 | 2010 | 74 | 0.190 |
Why?
| | Medicare | 1 | 2005 | 663 | 0.180 |
Why?
| | Psychology, Adolescent | 1 | 2000 | 63 | 0.180 |
Why?
| | Food Safety | 1 | 2020 | 17 | 0.180 |
Why?
| | Reproduction | 1 | 2021 | 189 | 0.180 |
Why?
| | Postpartum Hemorrhage | 1 | 2019 | 16 | 0.180 |
Why?
| | Dabigatran | 1 | 2019 | 26 | 0.180 |
Why?
| | Chronic Pain | 1 | 2023 | 211 | 0.180 |
Why?
| | Social Control, Formal | 1 | 2019 | 10 | 0.170 |
Why?
| | Nutritive Value | 1 | 2019 | 29 | 0.170 |
Why?
| | Organizational Affiliation | 2 | 2000 | 8 | 0.170 |
Why?
| | Food Supply | 1 | 2020 | 64 | 0.170 |
Why?
| | Computer Security | 1 | 2019 | 21 | 0.170 |
Why?
| | Retrospective Studies | 5 | 2022 | 12975 | 0.170 |
Why?
| | Secondary Prevention | 1 | 2020 | 227 | 0.170 |
Why?
| | Stakeholder Participation | 1 | 2019 | 69 | 0.170 |
Why?
| | Models, Theoretical | 2 | 2020 | 556 | 0.170 |
Why?
| | Schools | 1 | 2002 | 411 | 0.160 |
Why?
| | Antineoplastic Agents | 1 | 2009 | 1974 | 0.160 |
Why?
| | Pyridones | 1 | 2019 | 119 | 0.160 |
Why?
| | Health Risk Behaviors | 1 | 2018 | 13 | 0.160 |
Why?
| | Intersectoral Collaboration | 1 | 2018 | 60 | 0.160 |
Why?
| | Professional Practice | 1 | 1998 | 62 | 0.160 |
Why?
| | Morphine | 4 | 1987 | 134 | 0.160 |
Why?
| | Information Storage and Retrieval | 2 | 2015 | 124 | 0.160 |
Why?
| | Eating | 1 | 2020 | 369 | 0.160 |
Why?
| | Practice Management, Medical | 1 | 2018 | 35 | 0.160 |
Why?
| | Urinary Bladder, Overactive | 1 | 2018 | 20 | 0.160 |
Why?
| | Oral Health | 1 | 2020 | 148 | 0.160 |
Why?
| | United Kingdom | 3 | 2022 | 236 | 0.160 |
Why?
| | Food | 1 | 2019 | 162 | 0.160 |
Why?
| | Statistics as Topic | 1 | 2019 | 307 | 0.160 |
Why?
| | Patient Satisfaction | 2 | 2017 | 610 | 0.160 |
Why?
| | Rivaroxaban | 1 | 2019 | 208 | 0.160 |
Why?
| | Costs and Cost Analysis | 2 | 2022 | 202 | 0.160 |
Why?
| | Tuberculosis | 1 | 2020 | 240 | 0.150 |
Why?
| | Leadership | 1 | 2020 | 311 | 0.150 |
Why?
| | Food Handling | 1 | 2016 | 48 | 0.150 |
Why?
| | Health Resources | 1 | 2018 | 132 | 0.150 |
Why?
| | Linear Models | 2 | 2020 | 827 | 0.140 |
Why?
| | Patient Participation | 2 | 1997 | 369 | 0.140 |
Why?
| | Environmental Monitoring | 1 | 2018 | 296 | 0.140 |
Why?
| | Triclosan | 1 | 2016 | 9 | 0.140 |
Why?
| | Pregnancy | 6 | 2019 | 5691 | 0.140 |
Why?
| | Nutrition Assessment | 1 | 2016 | 78 | 0.140 |
Why?
| | Statistics, Nonparametric | 2 | 2012 | 403 | 0.140 |
Why?
| | Brain Chemistry | 2 | 1988 | 119 | 0.140 |
Why?
| | Pyrazoles | 1 | 2019 | 363 | 0.140 |
Why?
| | Patient Selection | 2 | 2011 | 675 | 0.140 |
Why?
| | Judgment | 1 | 2016 | 59 | 0.140 |
Why?
| | Information Centers | 1 | 1995 | 4 | 0.140 |
Why?
| | Endocrine Disruptors | 1 | 2016 | 35 | 0.140 |
Why?
| | Venous Thromboembolism | 1 | 2019 | 234 | 0.140 |
Why?
| | Thyroxine | 1 | 2016 | 63 | 0.140 |
Why?
| | Epidemiologic Research Design | 1 | 2016 | 30 | 0.140 |
Why?
| | Malnutrition | 1 | 2016 | 66 | 0.140 |
Why?
| | 5-Hydroxytryptophan | 2 | 1987 | 22 | 0.140 |
Why?
| | Adult | 8 | 2023 | 31510 | 0.140 |
Why?
| | Primary Health Care | 2 | 2020 | 1560 | 0.140 |
Why?
| | Calcium Channel Blockers | 1 | 1996 | 117 | 0.130 |
Why?
| | Sex Factors | 2 | 2012 | 1781 | 0.130 |
Why?
| | Infant, Newborn | 2 | 2020 | 5255 | 0.130 |
Why?
| | Surveys and Questionnaires | 6 | 2022 | 4708 | 0.130 |
Why?
| | Health | 1 | 2015 | 81 | 0.130 |
Why?
| | Depression | 1 | 2003 | 1132 | 0.130 |
Why?
| | Ranibizumab | 1 | 2014 | 18 | 0.130 |
Why?
| | Depressive Disorder | 1 | 2018 | 333 | 0.130 |
Why?
| | Italy | 1 | 2014 | 90 | 0.130 |
Why?
| | Medical Informatics | 1 | 2015 | 102 | 0.120 |
Why?
| | Hypertension | 2 | 2010 | 1203 | 0.120 |
Why?
| | Adverse Drug Reaction Reporting Systems | 2 | 2011 | 69 | 0.120 |
Why?
| | Nursing Staff, Hospital | 1 | 2016 | 123 | 0.120 |
Why?
| | Legislation, Food | 1 | 2013 | 2 | 0.120 |
Why?
| | Bevacizumab | 1 | 2014 | 124 | 0.120 |
Why?
| | Food Additives | 1 | 2013 | 7 | 0.120 |
Why?
| | Equipment Safety | 2 | 2010 | 38 | 0.120 |
Why?
| | History, 20th Century | 2 | 2007 | 281 | 0.120 |
Why?
| | Vaccination | 1 | 2022 | 1222 | 0.120 |
Why?
| | Nursing Homes | 1 | 2015 | 130 | 0.120 |
Why?
| | Combined Modality Therapy | 1 | 2016 | 1166 | 0.120 |
Why?
| | Lung Neoplasms | 2 | 2005 | 2220 | 0.120 |
Why?
| | Search Engine | 1 | 2013 | 15 | 0.110 |
Why?
| | Physician's Role | 1 | 2015 | 200 | 0.110 |
Why?
| | Clinical Protocols | 2 | 2009 | 238 | 0.110 |
Why?
| | Health Services Research | 1 | 1996 | 385 | 0.110 |
Why?
| | Antipsychotic Agents | 1 | 2015 | 193 | 0.110 |
Why?
| | Health Planning Guidelines | 1 | 2012 | 25 | 0.110 |
Why?
| | Reimbursement Mechanisms | 1 | 2013 | 79 | 0.110 |
Why?
| | Total Quality Management | 1 | 2012 | 61 | 0.110 |
Why?
| | Random Allocation | 1 | 2013 | 344 | 0.110 |
Why?
| | Gastroenterology | 1 | 2014 | 158 | 0.110 |
Why?
| | Wounds and Injuries | 1 | 2019 | 772 | 0.100 |
Why?
| | Legislation, Drug | 2 | 2010 | 78 | 0.100 |
Why?
| | Switzerland | 1 | 2011 | 27 | 0.100 |
Why?
| | Americas | 1 | 2011 | 23 | 0.100 |
Why?
| | Middle Aged | 4 | 2021 | 27617 | 0.100 |
Why?
| | Diabetes Mellitus | 1 | 2020 | 942 | 0.100 |
Why?
| | Comprehension | 1 | 2013 | 163 | 0.100 |
Why?
| | Pain | 3 | 2023 | 735 | 0.100 |
Why?
| | Libraries | 1 | 2011 | 3 | 0.100 |
Why?
| | Mammography | 1 | 2012 | 126 | 0.100 |
Why?
| | Eclampsia | 1 | 2010 | 5 | 0.100 |
Why?
| | Cardiac Resynchronization Therapy Devices | 1 | 2011 | 14 | 0.100 |
Why?
| | Guatemala | 1 | 2012 | 296 | 0.100 |
Why?
| | Tocolytic Agents | 1 | 2010 | 16 | 0.100 |
Why?
| | Health Services Needs and Demand | 1 | 2013 | 254 | 0.100 |
Why?
| | Self Concept | 1 | 2012 | 215 | 0.100 |
Why?
| | Magnesium Sulfate | 1 | 2010 | 18 | 0.100 |
Why?
| | Prevalence | 3 | 2022 | 2326 | 0.100 |
Why?
| | Serotonin | 3 | 1987 | 309 | 0.100 |
Why?
| | Educational Status | 1 | 2012 | 437 | 0.090 |
Why?
| | Education, Pharmacy, Continuing | 1 | 2010 | 3 | 0.090 |
Why?
| | Quality Assurance, Health Care | 3 | 2012 | 325 | 0.090 |
Why?
| | Multicenter Studies as Topic | 1 | 2011 | 253 | 0.090 |
Why?
| | Time Factors | 1 | 2021 | 6412 | 0.090 |
Why?
| | Age Factors | 2 | 2012 | 2995 | 0.090 |
Why?
| | Health Surveys | 1 | 2012 | 454 | 0.090 |
Why?
| | Health Facilities | 1 | 2010 | 75 | 0.090 |
Why?
| | Informed Consent | 1 | 2011 | 163 | 0.090 |
Why?
| | Rats, Inbred Strains | 5 | 1988 | 394 | 0.090 |
Why?
| | Mental Disorders | 1 | 2018 | 939 | 0.090 |
Why?
| | Mandatory Programs | 1 | 2009 | 16 | 0.090 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2014 | 1945 | 0.090 |
Why?
| | Prostheses and Implants | 1 | 2010 | 141 | 0.090 |
Why?
| | Reproducibility of Results | 5 | 2016 | 2874 | 0.090 |
Why?
| | Disasters | 1 | 2010 | 89 | 0.090 |
Why?
| | Vinyl Chloride | 1 | 2009 | 2 | 0.090 |
Why?
| | Heart-Assist Devices | 1 | 2015 | 485 | 0.090 |
Why?
| | Growth Hormone | 2 | 1987 | 108 | 0.090 |
Why?
| | Lead Poisoning | 1 | 2009 | 18 | 0.090 |
Why?
| | Financing, Government | 1 | 2009 | 40 | 0.080 |
Why?
| | Placebos | 1 | 2009 | 202 | 0.080 |
Why?
| | Multivariate Analysis | 2 | 2006 | 1474 | 0.080 |
Why?
| | Methadone | 2 | 1987 | 69 | 0.080 |
Why?
| | Silicosis | 1 | 2009 | 21 | 0.080 |
Why?
| | Radiology | 1 | 2012 | 199 | 0.080 |
Why?
| | Learning | 1 | 2012 | 374 | 0.080 |
Why?
| | Smartphone | 2 | 2019 | 67 | 0.080 |
Why?
| | Rats | 8 | 2016 | 5392 | 0.080 |
Why?
| | Socioeconomic Factors | 1 | 2012 | 1129 | 0.080 |
Why?
| | Pre-Eclampsia | 1 | 2010 | 183 | 0.080 |
Why?
| | Motivation | 2 | 2020 | 506 | 0.080 |
Why?
| | Helsinki Declaration | 1 | 2007 | 2 | 0.080 |
Why?
| | Coronary Disease | 1 | 2010 | 356 | 0.080 |
Why?
| | Health Plan Implementation | 1 | 2008 | 133 | 0.080 |
Why?
| | Logistic Models | 2 | 2006 | 1901 | 0.080 |
Why?
| | Adolescent | 4 | 2010 | 18479 | 0.080 |
Why?
| | Longitudinal Studies | 2 | 2022 | 2513 | 0.080 |
Why?
| | Aged | 5 | 2014 | 19656 | 0.080 |
Why?
| | Reference Values | 1 | 2009 | 774 | 0.080 |
Why?
| | Receptors, Dopamine | 1 | 1987 | 13 | 0.080 |
Why?
| | Propylamines | 1 | 1987 | 12 | 0.080 |
Why?
| | Financing, Organized | 3 | 2003 | 34 | 0.080 |
Why?
| | Persuasive Communication | 1 | 2007 | 13 | 0.070 |
Why?
| | Receptors, Serotonin | 1 | 1987 | 33 | 0.070 |
Why?
| | Consumer Behavior | 2 | 2004 | 64 | 0.070 |
Why?
| | Cardiology | 1 | 2009 | 272 | 0.070 |
Why?
| | Fluoxetine | 1 | 1987 | 47 | 0.070 |
Why?
| | Culture | 1 | 2007 | 129 | 0.070 |
Why?
| | Regression Analysis | 1 | 2009 | 983 | 0.070 |
Why?
| | Receptors, Adrenergic, alpha | 1 | 1986 | 32 | 0.070 |
Why?
| | United States Public Health Service | 1 | 2006 | 8 | 0.070 |
Why?
| | Mothers | 1 | 2012 | 682 | 0.070 |
Why?
| | Hypothalamus | 1 | 1987 | 155 | 0.070 |
Why?
| | Ethics, Medical | 2 | 1999 | 73 | 0.070 |
Why?
| | Patient Readmission | 1 | 1991 | 633 | 0.070 |
Why?
| | Catecholamines | 1 | 1986 | 100 | 0.070 |
Why?
| | Prospective Studies | 5 | 2020 | 6471 | 0.070 |
Why?
| | United States Government Agencies | 1 | 2005 | 6 | 0.070 |
Why?
| | Geography | 1 | 2006 | 190 | 0.070 |
Why?
| | Forms and Records Control | 1 | 2005 | 23 | 0.070 |
Why?
| | Health Maintenance Organizations | 2 | 2003 | 96 | 0.070 |
Why?
| | Economic Competition | 1 | 2004 | 13 | 0.060 |
Why?
| | Alkaloids | 1 | 2004 | 23 | 0.060 |
Why?
| | Academies and Institutes | 1 | 2005 | 44 | 0.060 |
Why?
| | Mass Screening | 1 | 2012 | 1052 | 0.060 |
Why?
| | Anticonvulsants | 1 | 2006 | 184 | 0.060 |
Why?
| | Electronic Health Records | 1 | 2011 | 829 | 0.060 |
Why?
| | Health Care Coalitions | 1 | 2004 | 8 | 0.060 |
Why?
| | Genetic Engineering | 1 | 2004 | 83 | 0.060 |
Why?
| | Cyproheptadine | 4 | 1987 | 7 | 0.060 |
Why?
| | Emergency Service, Hospital | 2 | 2014 | 1864 | 0.060 |
Why?
| | Patient Safety | 2 | 2019 | 281 | 0.060 |
Why?
| | Odds Ratio | 2 | 2020 | 996 | 0.060 |
Why?
| | Labor Unions | 1 | 2003 | 3 | 0.060 |
Why?
| | United States Occupational Safety and Health Administration | 1 | 2003 | 8 | 0.060 |
Why?
| | Planning Techniques | 1 | 2003 | 14 | 0.060 |
Why?
| | Liability, Legal | 4 | 1995 | 39 | 0.060 |
Why?
| | Infant | 2 | 2021 | 8293 | 0.060 |
Why?
| | Japan | 1 | 2002 | 97 | 0.060 |
Why?
| | Inservice Training | 2 | 2016 | 106 | 0.060 |
Why?
| | Polyvinyls | 1 | 2002 | 17 | 0.060 |
Why?
| | Awareness | 1 | 2003 | 93 | 0.050 |
Why?
| | Hydroxyzine | 1 | 2022 | 6 | 0.050 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 1984 | 490 | 0.050 |
Why?
| | Databases as Topic | 1 | 2002 | 73 | 0.050 |
Why?
| | Administration, Cutaneous | 1 | 2002 | 119 | 0.050 |
Why?
| | Polymethacrylic Acids | 1 | 2002 | 61 | 0.050 |
Why?
| | Quality of Life | 2 | 2023 | 2366 | 0.050 |
Why?
| | Antibodies, Monoclonal | 1 | 1988 | 1284 | 0.050 |
Why?
| | Point-of-Care Systems | 1 | 2023 | 151 | 0.050 |
Why?
| | Pharmacy Service, Hospital | 2 | 1993 | 86 | 0.050 |
Why?
| | Heart Diseases | 1 | 2005 | 341 | 0.050 |
Why?
| | Hypoglycemic Agents | 1 | 2009 | 1032 | 0.050 |
Why?
| | Patents as Topic | 1 | 2021 | 1 | 0.050 |
Why?
| | Feedback | 1 | 2002 | 153 | 0.050 |
Why?
| | Aged, 80 and over | 1 | 2012 | 6561 | 0.050 |
Why?
| | Varenicline | 1 | 2021 | 21 | 0.050 |
Why?
| | Maryland | 1 | 2000 | 36 | 0.050 |
Why?
| | Hand Hygiene | 1 | 2020 | 7 | 0.050 |
Why?
| | Perception | 1 | 2003 | 314 | 0.050 |
Why?
| | Radiologists | 1 | 2020 | 38 | 0.050 |
Why?
| | Journalism, Medical | 1 | 2000 | 6 | 0.050 |
Why?
| | Labor, Obstetric | 1 | 2000 | 53 | 0.050 |
Why?
| | Conservation of Natural Resources | 1 | 2002 | 107 | 0.050 |
Why?
| | Freedom | 1 | 2000 | 12 | 0.050 |
Why?
| | Music | 1 | 2000 | 36 | 0.050 |
Why?
| | Masks | 1 | 2020 | 48 | 0.050 |
Why?
| | Computer Graphics | 1 | 2020 | 48 | 0.050 |
Why?
| | Dentistry | 1 | 2020 | 12 | 0.050 |
Why?
| | Breast Neoplasms | 1 | 2012 | 1965 | 0.050 |
Why?
| | International Agencies | 1 | 2020 | 29 | 0.050 |
Why?
| | Death | 1 | 2000 | 105 | 0.050 |
Why?
| | Social Values | 1 | 2000 | 38 | 0.050 |
Why?
| | Social Perception | 1 | 2001 | 98 | 0.050 |
Why?
| | Cost of Illness | 1 | 2022 | 258 | 0.040 |
Why?
| | Public Health Surveillance | 1 | 2020 | 58 | 0.040 |
Why?
| | Patient Compliance | 1 | 2003 | 537 | 0.040 |
Why?
| | Ethics | 2 | 1996 | 6 | 0.040 |
Why?
| | Insulin | 1 | 2009 | 2162 | 0.040 |
Why?
| | Electrocardiography | 1 | 2022 | 556 | 0.040 |
Why?
| | Employment | 1 | 2020 | 135 | 0.040 |
Why?
| | Patient Care Team | 1 | 2003 | 521 | 0.040 |
Why?
| | Foundations | 1 | 2018 | 22 | 0.040 |
Why?
| | Contracts | 1 | 1998 | 9 | 0.040 |
Why?
| | Social Behavior | 1 | 2001 | 276 | 0.040 |
Why?
| | Breast Feeding | 1 | 2021 | 386 | 0.040 |
Why?
| | Fiji | 1 | 2017 | 3 | 0.040 |
Why?
| | Health Status Indicators | 1 | 1998 | 154 | 0.040 |
Why?
| | Consensus | 1 | 2019 | 534 | 0.040 |
Why?
| | Technology Assessment, Biomedical | 1 | 1997 | 29 | 0.040 |
Why?
| | Forecasting | 1 | 2018 | 353 | 0.040 |
Why?
| | Sampling Studies | 1 | 1996 | 92 | 0.040 |
Why?
| | Capacity Building | 1 | 2016 | 51 | 0.040 |
Why?
| | Child, Preschool | 1 | 2010 | 9491 | 0.040 |
Why?
| | Animals, Newborn | 3 | 1987 | 806 | 0.040 |
Why?
| | Diffusion of Innovation | 1 | 1997 | 98 | 0.040 |
Why?
| | CD-ROM | 1 | 1995 | 7 | 0.030 |
Why?
| | Medical Informatics Applications | 1 | 1995 | 9 | 0.030 |
Why?
| | Anti-Infective Agents, Local | 1 | 2016 | 42 | 0.030 |
Why?
| | Air Pollution | 1 | 2018 | 209 | 0.030 |
Why?
| | Developed Countries | 1 | 1995 | 32 | 0.030 |
Why?
| | Models, Statistical | 1 | 2020 | 636 | 0.030 |
Why?
| | Software | 1 | 2020 | 613 | 0.030 |
Why?
| | Regional Medical Programs | 1 | 1995 | 4 | 0.030 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2009 | 2174 | 0.030 |
Why?
| | Analysis of Variance | 1 | 1998 | 1293 | 0.030 |
Why?
| | Communication Barriers | 1 | 1996 | 94 | 0.030 |
Why?
| | DNA-Binding Proteins | 1 | 2022 | 1346 | 0.030 |
Why?
| | Influenza, Human | 1 | 2020 | 554 | 0.030 |
Why?
| | Drugs, Investigational | 1 | 2015 | 31 | 0.030 |
Why?
| | Palliative Care | 1 | 2000 | 629 | 0.030 |
Why?
| | Poison Control Centers | 1 | 1995 | 84 | 0.030 |
Why?
| | Drug Contamination | 1 | 2013 | 54 | 0.030 |
Why?
| | Education, Medical, Undergraduate | 1 | 1995 | 199 | 0.030 |
Why?
| | Drug Stability | 1 | 2013 | 153 | 0.030 |
Why?
| | Solubility | 1 | 2013 | 235 | 0.030 |
Why?
| | Family Practice | 1 | 1996 | 438 | 0.030 |
Why?
| | Hospital Bed Capacity, 300 to 499 | 1 | 1991 | 5 | 0.030 |
Why?
| | Dementia | 1 | 2015 | 208 | 0.030 |
Why?
| | Precision Medicine | 1 | 2015 | 363 | 0.030 |
Why?
| | Confidence Intervals | 1 | 2012 | 324 | 0.020 |
Why?
| | Referral and Consultation | 2 | 1995 | 648 | 0.020 |
Why?
| | Dissent and Disputes | 1 | 2011 | 18 | 0.020 |
Why?
| | National Health Programs | 1 | 2010 | 21 | 0.020 |
Why?
| | Zambia | 1 | 2010 | 67 | 0.020 |
Why?
| | Observer Variation | 1 | 1991 | 309 | 0.020 |
Why?
| | Chronic Disease | 1 | 2016 | 1636 | 0.020 |
Why?
| | Public Health Practice | 1 | 2010 | 62 | 0.020 |
Why?
| | Training Support | 1 | 2010 | 24 | 0.020 |
Why?
| | Midwifery | 1 | 2010 | 41 | 0.020 |
Why?
| | Geriatric Assessment | 1 | 1991 | 185 | 0.020 |
Why?
| | San Francisco | 3 | 1995 | 57 | 0.020 |
Why?
| | Endpoint Determination | 1 | 2009 | 69 | 0.020 |
Why?
| | beta-Endorphin | 1 | 1988 | 7 | 0.020 |
Why?
| | Migraine Disorders | 1 | 2009 | 79 | 0.020 |
Why?
| | Obstetrics | 1 | 2010 | 162 | 0.020 |
Why?
| | Aging | 3 | 1987 | 1670 | 0.020 |
Why?
| | Immunoglobulin Fab Fragments | 1 | 1988 | 69 | 0.020 |
Why?
| | Molecular Weight | 1 | 1988 | 343 | 0.020 |
Why?
| | Iodine Radioisotopes | 1 | 1988 | 130 | 0.020 |
Why?
| | Enkephalin, D-Penicillamine (2,5)- | 1 | 1987 | 1 | 0.020 |
Why?
| | 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer | 1 | 1987 | 3 | 0.020 |
Why?
| | Endorphins | 1 | 1987 | 7 | 0.020 |
Why?
| | Enkephalins | 1 | 1987 | 13 | 0.020 |
Why?
| | Receptors, Opioid, kappa | 1 | 1987 | 11 | 0.020 |
Why?
| | Dynorphins | 1 | 1987 | 9 | 0.020 |
Why?
| | Early Detection of Cancer | 1 | 2012 | 360 | 0.020 |
Why?
| | Hydrazines | 1 | 1987 | 31 | 0.020 |
Why?
| | Receptors, Opioid, mu | 1 | 1987 | 52 | 0.020 |
Why?
| | Pyrrolidines | 1 | 1987 | 57 | 0.020 |
Why?
| | p-Chloroamphetamine | 1 | 1987 | 1 | 0.020 |
Why?
| | 5,7-Dihydroxytryptamine | 1 | 1987 | 4 | 0.020 |
Why?
| | Bipolar Disorder | 1 | 2009 | 209 | 0.020 |
Why?
| | Hydroxyindoleacetic Acid | 1 | 1987 | 18 | 0.020 |
Why?
| | Reserpine | 1 | 1986 | 6 | 0.020 |
Why?
| | Sympatholytics | 1 | 1986 | 15 | 0.020 |
Why?
| | Haloperidol | 1 | 1986 | 36 | 0.020 |
Why?
| | Corticosterone | 1 | 1987 | 253 | 0.020 |
Why?
| | Norepinephrine | 1 | 1986 | 212 | 0.020 |
Why?
| | Hypothalamo-Hypophyseal System | 1 | 1987 | 195 | 0.020 |
Why?
| | Piperazines | 1 | 1987 | 316 | 0.020 |
Why?
| | Electrochemistry | 1 | 1984 | 69 | 0.020 |
Why?
| | Clinical Competence | 1 | 2010 | 951 | 0.010 |
Why?
| | Peptide Fragments | 1 | 1987 | 702 | 0.010 |
Why?
| | Dopamine | 1 | 1986 | 249 | 0.010 |
Why?
| | Fetus | 1 | 1987 | 690 | 0.010 |
Why?
| | Reading | 1 | 2002 | 157 | 0.010 |
Why?
| | Alendronate | 1 | 2000 | 7 | 0.010 |
Why?
| | Pravastatin | 1 | 2000 | 29 | 0.010 |
Why?
| | Television | 1 | 2000 | 71 | 0.010 |
Why?
| | Outpatients | 2 | 1993 | 325 | 0.010 |
Why?
| | Anticholesteremic Agents | 1 | 2000 | 130 | 0.010 |
Why?
| | Aspirin | 1 | 2000 | 334 | 0.010 |
Why?
| | European Union | 1 | 1997 | 9 | 0.010 |
Why?
| | Clinical Trials, Phase IV as Topic | 1 | 1995 | 3 | 0.010 |
Why?
| | Fees, Medical | 1 | 1995 | 9 | 0.010 |
Why?
| | Hotlines | 1 | 1995 | 25 | 0.010 |
Why?
| | Physicians' Offices | 1 | 1995 | 16 | 0.010 |
Why?
| | Home Nursing | 1 | 1995 | 27 | 0.010 |
Why?
| | Hospital Charges | 1 | 1995 | 42 | 0.010 |
Why?
| | Propofol | 1 | 1995 | 49 | 0.010 |
Why?
| | Poisoning | 1 | 1995 | 109 | 0.010 |
Why?
| | Insurance, Health | 1 | 1995 | 244 | 0.010 |
Why?
| | Medication Errors | 1 | 1993 | 92 | 0.010 |
Why?
| | Frail Elderly | 1 | 1993 | 107 | 0.010 |
Why?
| | Hospitals, Community | 1 | 1992 | 49 | 0.010 |
Why?
| | Medical Staff, Hospital | 1 | 1992 | 76 | 0.010 |
Why?
| | Curriculum | 1 | 1995 | 910 | 0.010 |
Why?
| | Endocrine Glands | 1 | 1987 | 16 | 0.000 |
Why?
| | Alcoholic Beverages | 1 | 1987 | 17 | 0.000 |
Why?
| | Narcotics | 1 | 1987 | 50 | 0.000 |
Why?
| | Maternal-Fetal Exchange | 1 | 1987 | 157 | 0.000 |
Why?
| | Follow-Up Studies | 1 | 1995 | 4596 | 0.000 |
Why?
| | Cocaine | 1 | 1987 | 158 | 0.000 |
Why?
| | Marijuana Abuse | 1 | 1987 | 209 | 0.000 |
Why?
| | Child Development | 1 | 1987 | 410 | 0.000 |
Why?
| | Disease Models, Animal | 1 | 1987 | 3730 | 0.000 |
Why?
|
|
Bero's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|